ID: ALA1254654

Max Phase: Preclinical

Molecular Formula: C22H24F2N4O2

Molecular Weight: 414.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)cc1

Standard InChI:  InChI=1S/C22H24F2N4O2/c23-17-6-4-16(5-7-17)20(29)25-10-13-27-11-8-22(9-12-27)21(30)26-15-28(22)19-3-1-2-18(24)14-19/h1-7,14H,8-13,15H2,(H,25,29)(H,26,30)

Standard InChI Key:  AUTVGUGBVJTDOF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 414.46

Molecular Weight (Monoisotopic): 414.1867

AlogP: 2.12

#Rotatable Bonds: 5

Polar Surface Area: 64.68

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.40

CX Basic pKa: 7.69

CX LogP: 2.33

CX LogD: 1.86

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.79

Np Likeness Score: -1.33

References

1. Lavieri RR, Scott SA, Selvy PE, Kim K, Jadhav S, Morrison RD, Daniels JS, Brown HA, Lindsley CW..  (2010)  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.,  53  (18): [PMID:20735042] [10.1021/jm100814g]

2. O'Reilly MC, Scott SA, Brown KA, Oguin TH, Thomas PG, Daniels JS, Morrison R, Brown HA, Lindsley CW..  (2013)  Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.,  56  (6): [PMID:23445448] [10.1021/jm301782e]

Source

Source(1):

• Scientific Literature